BeyondSpring Inc. Contract Liability (Deferred Revenue)
BeyondSpring Inc. (BYSI) had Contract Liability (Deferred Revenue) of $2.00 million as of 2024-06-30, per its 6-K filed 2024-08-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-08-29
- 2024-06-30: Contract with Customer, Liability, Current $2.00M.
- 2023-12-31: Contract with Customer, Liability, Current $1.75M.
- 2023-06-30: Contract with Customer, Liability, Current $1.75M.
- 2022-12-31: Contract with Customer, Liability, Current $1.35M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2024-06-30 | $2.00M 6-K · filed 2024-08-29 |
| 2023-12-31 | $1.75M 6-K · filed 2024-08-29 |
| 2023-06-30 | $1.75M 6-K · filed 2024-02-02 |
| 2022-12-31 | $1.35M 6-K · filed 2024-02-02 |
| 2022-06-30 | $1.35M 6-K · filed 2023-02-28 |
| 2021-12-31 | $1.37M 20-F · filed 2023-04-18 |
| 2021-09-30 | $1.53M 6-K · filed 2021-12-30 |
| 2021-06-30 | $1.35M 6-K · filed 2021-09-10 |
| 2021-03-31 | $1.35M 6-K · filed 2021-06-16 |
| 2020-12-31 | $1.35M 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |